Variation in antibiotic use in the European Union.

By O. Cars, S. Mölstad, A. Melander. The Lancet, 2001

748 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

New insights into the management of acne: an update from the Global Alliance to Improve Outcomes in Acne group. (2009, background): “Prescribing practices for acne have been shown to influence the resistance rate.(82,83) Data from a European surveillance study of P acnes were correlated with published data on outpatient antibiotic sales.”
European Position Paper on Rhinosinusitis and Nasal Polyps 2012. (2012, background): “A validation study has shown ‘mild disease’ to be defined as a VAS score of 0-3 inclusive, moderate as >3-7 inclusive, and severe as ≥7. In general, overall quality of life is more likely to be affected with scores of 5 or more ((1083)).”
Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. (2008, background): “We found the disparity in the level of use among controls from different countries that was expected from published prescription data (Cars et al., 2001).”
Antibiotics in the aquatic environment--a review--part I. (2009, methodology): “Cars et al. (2001) obtained data for non-hospital antibiotic sales for 1997 from the 15 member states and analysed these according to the Anatomic Therapeutic Chemical (ATC) classification system, and expressed them as defined daily doses per 1000 people per day.”